Two spontaneous null mutations in the mouse Sharpin gene (Sharpincpdm and Sharpincpdm-Dem) result in the chronic proliferative dermatitis mouse (Locus symbol: cpdm) phenotype which appears to be a homologue of human idiopathic hypereosinophilic syndromes. SHARPIN is critical in the development and function of the immune system, and also plays an important role in cell proliferation, differentiation, apoptosis, and cancer through the NFKB, integrin, and Toll-like receptor (TLR) signaling networks. Our overall hypothesis is that SHARPIN functions in multiple overlapping biochemical pathways resulting in a complex phenotype upon loss of function. By unraveling the pathogenesis of the disease in skin and other organ systems and confirming the human homologue, we will identify novel and better methods for the diagnosis and treatment of patients. Our new conditional Sharpin null mouse (B6(Cg)-Tyrc-2J Sharpintm1Sun/Sun) provides a novel tool to investigate, with great precision, the role of this recently discovered gene in the NFKB, integrin, and TLR signaling networks. Loss of SHARPIN results in different patterns of network activation based on cell type. To define how each cell type responds, we will selectively inactivate Sharpin in keratinocytes, fibroblasts, endothelial cells, adipose tissue, various subsets of lymphocytes, etc. using cell-specific promoters driving cre-recombinase. Concurrently, we will inactivate specific points in the three major gene networks under investigation by creating compound mutants with our Sharpin null mice of conditional nulls. These approaches will define the key cell types involved in the pathogenesis of this hypereosinophilic syndrome and dissect how Sharpin functions within three major signaling networks. A prominent feature of the cpdm phenotype is chronic dermatitis with many eosinophils and overexpression of type 2 cytokines along with a diminished systemic type 1 immune response. Dendritic cells play a pivotal role in directing the type of immune and inflammatory responses. We will address the mechanism underlying the chronic type 2 inflammation through selective deletion of Sharpin in dendritic cells and deletion of specific cytokine genes. A complementary approach builds on our observation that loss of Sharpin in different inbred strains had a dramatic effect on severity of disease indicating strain specific major modifying genes were involved. We will validate a recently identified major candidate gene. In addition, by using quantitative trait locus mapping and gene association studies, we will identify other genes that regulate this phenotype, most likely those involved in regulating NFKB, integrin, and TLR signaling networks. Lastly, we will utilize several de-identified human blood/DNA repositories to screen human patients with hypereosinophilic syndromes to determine which of these human diseases our chronic proliferative dermatitis mutant mice most closely resemble.
Human hypereosinophilic syndrome (HES) is a group of diseases that can be life threatening. Little is known about their cause. We have discovered two spontaneous mutant mice that are caused by null mutations in the Sharpin gene. By screening human HES patients and those with eosinophilic esophagitis for mutations in this gene, using several de-identified DNA repositories, we will determine which form(s) of HES and/or eosinophilic esophagitis are homologous to our mouse models. We will also determine genetic polymorphisms (modifier genes) in our mouse models, including our recently identified major modifier candidate gene, and compare these with polymorphisms in patient DNA for the same gene(s). In so doing we will develop a genetic assay to correctly diagnose HES and eosinophilic esophagitis patients. Our spontaneous mouse models provided tools to dissect the molecular pathogenesis of this disease. We will utilize our novel conditional null allelic mutation to selectively inactivate Sharpin function to refine our understandings of the disease mechanisms involved and provide pharmacological targets, which can then be tested in our mouse models, as we have done successfully to date for a limited number of approaches. Taken together, we have the tools to 1) define the pathogenesis of some forms of human HES and eosinophilic esophagitis, 2) identify targets and drugs that might effectively treat these diseases, and 3) test compounds in preclinical trials for efficacy and safety. These approaches provide new hope for a disease for which there are currently few options.
|Potter, Christopher S; Wang, Zhe; Silva, Kathleen A et al. (2014) Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling. PLoS One 9:e85666|
|Seymour, Rosemarie; Shirley, Bobbi-Jo; Hogenesch, Harm et al. (2013) Loss of function of the mouse Sharpin gene results in Peyer's patch regression. PLoS One 8:e55224|
|Pouwels, Jeroen; De Franceschi, Nicola; Rantakari, Pia et al. (2013) SHARPIN regulates uropod detachment in migrating lymphocytes. Cell Rep 5:619-28|
|Fleckman, Philip; Jaeger, Karin; Silva, Kathleen A et al. (2013) Comparative anatomy of mouse and human nail units. Anat Rec (Hoboken) 296:521-32|
|Wang, Zhe; Potter, Christopher S; Sundberg, John P et al. (2012) SHARPIN is a key regulator of immune and inflammatory responses. J Cell Mol Med 16:2271-9|
|Wang, Zhe; Sokolovska, Anna; Seymour, Rosemarie et al. (2012) SHARPIN is essential for cytokine production, NF-ýýB signaling, and induction of Th1 differentiation by dendritic cells. PLoS One 7:e31809|
|Sundberg, J P; Silva, K A (2012) What color is the skin of a mouse? Vet Pathol 49:142-5|
|Liang, Yanhua; Sundberg, John P (2011) SHARPIN regulates mitochondria-dependent apoptosis in keratinocytes. J Dermatol Sci 63:148-53|
|Ikeda, Fumiyo; Deribe, Yonathan Lissanu; Skanland, Sigrid S et al. (2011) SHARPIN forms a linear ubiquitin ligase complex regulating NF-ýýB activity and apoptosis. Nature 471:637-41|
|Liang, Yanhua; Seymour, Rosemarie E; Sundberg, John P (2011) Inhibition of NF-?B signaling retards eosinophilic dermatitis in SHARPIN-deficient mice. J Invest Dermatol 131:141-9|
Showing the most recent 10 out of 20 publications